Citigroup released a research report on November 5th, stating that innovent bio announced the termination of the Fortvita subscription trade. The company's management mentioned during an investor meeting that the original intention of this trade was to accelerate the development of Fortvita's overseas business. After the termination of the trade, Fortvita currently has no further financing plans. Looking ahead, the bank believes that the group's strong sales performance and overseas clinical progress will sustainably restore investor confidence, rating it as a "buy" with a target price of 55 Hong Kong dollars.